Member Login
  1. Stocks
    2. /
  2. AstraZeneca PLC (LSE: AZN)
    3. /

LSE:AZN (AstraZeneca PLC)

About AZN

AstraZeneca is a biopharmaceutical business that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three main therapy areas - Respiratory, Inflammation and Autoimmunity (RIA), Cardiovascular and Metabolic Disease (CVMD) and Oncology – as well as in Infection and Neuroscience.
Financial Market Data copyright © 2026 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.

AstraZeneca PLC (LSE: AZN) Latest News

Company Comment

Betting On AstraZeneca plc’s Drug Pipeline

| Owain Bennallack

What’s caused £41 billion drugs maker AstraZeneca plc (LON:AZN) to become afflicted by a seemingly interminable wasting disease?

Read more »

Investing Videos

A Closer Look At AstraZeneca plc

| Jill Ralph

VIDEO: Two Fools analyse AstraZeneca plc (LON: AZN).

Read more »

Company Comment

Earnings Drop 16% At AstraZeneca Plc

| Nate Weisshaar

Investing the future while revenues fall takes its toll on the bottom line at AstraZeneca plc (LON:AZN).

Read more »

Investing Articles

Why You Might Think Of Investing In This FTSE Underdog: AstraZeneca plc

| Tony Reading

AstraZeneca plc (LON: AZN) could be a contrarian investment opportunity.

Read more »

Investing Articles

Why Reinvesting Your Dividends Is The Best Decision You’ll Ever Make

| Rupert Hargreaves

Dividend reinvestment is a great way to achieve market beating returns without much effort.

Read more »

Company Comment

2 Big Problems For GlaxoSmithKline Plc

| Leo Sun

It's been a rough year for pharmaceutical giant GlaxoSmithKline plc (LON: GSK).

Read more »

Investing Articles

4 Ways AstraZeneca plc Will Continue To Lead The Biotechnology Sector

| Rupert Hargreaves

How does AstraZeneca plc (LON: AZN) compare to its sector peers?

Read more »

Investing Articles

Why I Hate AstraZeneca plc

| Harvey Jones

Aside from its 5.6% yield, Harvey Jones finds little to love about AstraZeneca plc (LON: AZN).

Read more »

Investing Articles

4 Ways GlaxoSmithKline plc Will Continue To Lag The Biotechnology Sector

| Rupert Hargreaves

How does GlaxoSmithKline plc (LON: GSK) compare to its sector peers?

Read more »

Investing Articles

21 Worrying Reasons Which Make AstraZeneca plc A Sell

| Royston Wild

Royston Wild reveals why shares in AstraZeneca plc (LON: AZN) are ready to shuttle lower.

Read more »

Investing Articles

News Flow Makes Me Want To Buy AstraZeneca plc

| Peter Stephens

I’m thinking of buying AstraZeneca plc (LON: AZN) and here’s why…

Read more »

Investing Articles

Neil Woodford: The Surprising Hero Of British Biotech

| G A Chester

Funding for British biotech has been drying up, but ace City investor Neil Woodford has ridden to the rescue.

Read more »